Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape
Aerial View of Thames Estuary
There’s a lot of interest in the potential for γδ T cells for cancer immunotherapy with multiple US, UK and EU companies already active in the area, not to mention the Chinese too.
Now that we have a grounding in the science behind what role γδ T cells play in our immune system, what they ‘see’ and do, we can better consider how companies are translating basic research into therapeutics.
In this third post in our mini-series, we’re taking a closer look at the emerging new product development landscape.
This post is not intended to be a definitive analysis or report on the whole γδ T cell therapy landscape, instead we’ve chosen to highlight a few leading companies and use them as examples to illustrate different translational approaches that are being investigated. A report on developments in China will follow separately tomorrow.
Some companies are looking at adoptive cell therapy, others have monoclonal antibodies or bispecific antibodies in development.
To learn more from our latest thought leader interview and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
